FibroBiologics Inc. (NASDAQ: FBLG) announced it will begin patient enrollment in the second quarter of 2026 for its clinical trial of CYWC628, an investigational fibroblast-based therapy for diabetic foot ulcers.

The Houston-based biotechnology company completed initial site activation for the trial and expects to report topline data by the end of 2026. CYWC628 is designed to address diabetic foot ulcers by utilizing the regenerative and immune-modulating properties of fibroblasts.

Chief Executive Officer Pete O'Heeron stated in a letter to shareholders that the company's current capital plan provides resources to operate through the topline data from this trial. The company holds more than 270 issued and pending patents across various clinical pathways.

Diabetic foot ulcers affect more than 33 million patients worldwide, according to the company's statement. The condition remains associated with high amputation and recurrence rates despite existing treatment options.

FibroBiologics also continues to advance programs in multiple sclerosis and psoriasis, supported by ongoing preclinical work. The company is developing its artificial thymus organoid platform as part of its broader pipeline focused on cellular dysfunction diseases.

The clinical trial represents the company's transition from development to clinical execution after years of building technology and infrastructure. FibroBiologics focuses on developing therapeutics using fibroblasts and fibroblast-derived materials for chronic diseases.